ImmuneRegen BioSciences Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ImmuneRegen BioSciences Inc.
Scancell and ImmuneRegen look at combining vaccine technologies
UK therapeutic cancer vaccine developer Scancell Holdings and ImmuneRegen BioSciences are to investigate whether their technologies could be combined to develop improved product efficacy.
Deals Update (08/2007)
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice